drugs as causative agents and therapeutic agents in inflammatory bowel disease
Clicks: 257
ID: 236055
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
257 views
55 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #36 of 88 articles by views in energy policy
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Ulcerative colitis and Crohn's disease are collectively known as inflammatory bowel diseases (IBD) which are chronic inflammatory disorders of gastrointestinal tract. The etiopathogenesis of IBD has been extensively studied but not fully revealed. Recent advances in physiology, molecular biology and pharmacology have provided some insight into the basic etiopathogenetic causes such as genetic, immunologic, etc. This review focuses on drugs involved in the cause of the disease and the investigational new drugs, current therapeutic strategies and their clinical benefits.
| Reference Key |
kondamudi2013actadrugs
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Phani Krishna Kondamudi;Rajkumar Malayandi;Chandramohan Eaga;Deepika Aggarwal |
| Journal | energy policy |
| Year | 2013 |
| DOI |
10.1016/j.apsb.2013.06.004
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.